A phase I clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and preliminary efficacy of SCB-219M in patients with chemotherapy-induced thrombocytopenia (CIT): An interim analysis. (ASCO 2024) - Apr 25, 2024 - Abstract #e15015; P1 | "Incidence of CIT can occur in about 15-25% of patients undergoing standard chemotherapy regiments with platinum, taxane and/or gemcitabine-based regimen. In this interim analysis, drug safety, PK profile and durable efficacy are expected to support SCB-219M dosing interval of ≥2-weeks or a single dosing regimen within a chemotherapy cycle. Accordingly, a Phase Ib trial evaluating repeated dosing of SCB-219M is planned to initiate in 2024. Clinical trial information: NCT05426369."
Clinical • P1 data • PK/PD data • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • Thrombocytopenia
|
|
Yongsheng Wang; Ke Xie; Nan Xu; Yuyao Yi; Shan Huang; Bin Ye; Xing Gao; Wei Tan; May Yang; Danmei Su; Rong Xu; Jing Yuan; Peng Liang
|